Objective:To retrospectively evaluate efficacy and safety of 0.05％ halometasone/1％ triclosan cream (Hal/TCS) in treating truncal vitiligo of children and adolescents.Methods:We retrospectively reviewed the records of children and adolescents with truncal vitiligo treated only with topical Hal/TCS twice daily or only with topical 0.1％ mometasone furoate cream (mometasone) twice daily for at least 3 months,and collected relevant data.Efficacy outcomes included patients\' mean repigmentation score after 1-and 3-month treatment calculated based on patients\' repigmentation percentage,and effective rate (percentage of patients with ＞50％ repigmentation).Subgroup analyses of patients\' mean repigmentation score based on their age,vitiligo stage,and duration were conducted.Rate of adverse events were calculated.Results:One hundred and twenty-two eligible patients were included,among them,63 and 59 patients were in the Hal/TCS group and the mometasone group,respectively.After 3 months of treatment,the Hal/TCS group had significantly higher mean repigmentation score and effective rate than the mometasone group (53.49 ± 28.33 vs.41.46+ 27.16,P =0.02;53.97％ vs.35.59％,P =0.04,respectively).Patients with shorter disease duration (＜ 12 months) and patients with progressive vitiligo responded significantly better to the Hal/TCS treatment than patients with longer disease duration and patients with stable vitiligo,respectively.Both treatments were well tolerated and the two treatment groups had comparable rates of adverse events.Conclusions:Short-term Hal/TCS treatment was effective,well-tolerated,and safe in treating vitiligo in the trunk of children and adolescents.